Hypereosinophilic Syndrome Treatment Study
A Multicentre, Randomised, Doubleblind, Parallel-group, Placebo controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)
- Sex: Any
- Age: Child (Birth - 17), Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Hypereosinophilic Syndrome
Study Purpose
HES (Hypereosinophilic Syndrome) is a disease characterized by high levels of eosinophils (a particular type of white blood cell) in your blood and a build-up of eosinophils in some organs and tissues (like skin, heart, lungs, intestines or others) causing their dysfunction. Benralizumab is an antibody (i.e. biologic drug) that has been made to reduce the number of eosinophils in the body. A previous benralizumab HES study showed that benralizumab may reduce eosinophils in blood and tissues in patients with severe HES that is not well controlled by standard of care medications. The purpose of this study is to see if benralizumab, given as injections under the skin, can help control your HES better if it is added to available standard of care HES medications which you are currently taking
Who Can Participate
Age: 12 years and older
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
UH Landerbrook Health Center
5850 Landerbrook Dr
Mayfield Heights OH, 44124
UH Solon Health Center
34055 Solon Rd
Solon OH, 44139
- UH IRB: SITE00001311
- StudyID: 2021-0516
- ClinicalTrials.gov: NCT04191304
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422